Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7535-7544

  Veltkamp, Stephan A ^a   Witteveen, Els O ^d   Capriati, Angela ^e   Crea, Attilio ^e   Animati, Fabio ^e   Voogel Fuchs, Marja ^a   Van Den Heuvel, Ingeborg J G M ^d   Beijnen, Jos H ^a,b,c   Voest, Emile E ^d   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DELIMOTECAN; DRUG METABOLITE; MEN 4901; T 0128; T 2513; UNCLASSIFIED DRUG; DEXTRAN; DRUG DERIVATIVE; PRODRUG; TOPOTECAN;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANUS CANCER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DYSPEPSIA; DYSPNEA; EXTRAVASATION; FATIGUE; FEMALE; FEVER; FLUSHING; HEAD AND NECK CANCER; HEADACHE; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OLIGURIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREMOR; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC AGENTS; DEXTRANS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PRODRUGS; TOPOTECAN;

EID: 58149343899     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0438     Document Type: Article

References (31)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
2. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
3. Dallavalle S, Giannini G, Alloatti D, et al. Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem 2006;49:5177-86.
4. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
5. Hsiang YH, Liu LF, Wall ME, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989;49:4385-9.
6. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
7. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
8. Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991;193:27-35.
9. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
10. Furuta T, Yokokura T. [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative]. GanTo Kagaku Ryoho 1990;17:121-30.
11. Fujita F, Koike M, Fujita M, et al. MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice. Clin Cancer Res 2005;11:1650-7.
12. Harada M, Imai J, Okuno S, Suzuki T. Macrophage-mediated activation of camptothecin analogue T-2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity. J Control Release 2000;69:389-97.
13. Binaschi M, Parlani M, Bellarosa D, et al. Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate. Anticancer Drugs 2006;17:1119-26.
14. Okuno S, Harada M, Yano T, et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res 2000;60:2988-95.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 1995;18:207-31.
17. Onishi H, Machida Y. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. Curr Drug Discov Technol 2005;2:169-83.
18. Vasey PA., Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999;5:83-94.
19. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JHM, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001;12:315-23.
20. Schoemaker NE, van Kesteren C, Rosing H, et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 2002;87:608-14.
21. Gerrits CJ, de Jonge MJ, Schellens JHM, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997;76:952-62.
22. Herben VM, Schellens JHM, Swart M, et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 1999;17:1897-905.
23. Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 1985;38:481-7.
24. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-5.
25. Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-600.
26. Ramchandani RP, Wang Y, Booth BP, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007;47:78-86.
27. Takimoto CH, Morrison G, Harold N, et al. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 2000;18:659-67.
28. Rothenberg ML, Kuhn JG, Burris HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
29. Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996;14:2688-95.
30. Schoemaker NE, Kuppens IE, Moiseyenko V, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004;91:1434-41.
31. Sasaki Y, Yoshida Y, Sudoh K, et al. Pharmacologic correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995;86:111-6.